BioQ Pharma Receives CE Mark for Second Infusion System
May 21, 2018
SAN FRANCISCO, May 21, 2018:
BioQ Pharma Incorporated (“the Company”), a specialty pharmaceutical company, today announced receipt of CE mark approval in the European Union for its Weight Dose Dispenser, a programable, single-use infusion pump.
The CE Mark demonstrates that BioQ’s Weight Dose Dispenser infusion product meets the essential requirements of all relevant European Medical Device Directives related to safety and performance. This product can be used to infuse a variety of pharmaceuticals that require weight based patient dosing.
Josh Kriesel, President and CEO of BioQ Pharma, commented, “We are delighted to announce that BioQ has received a CE Mark on another infusion product in our growing portfolio. This not only represents a technical milestone for the Company, but is also an achievement that should be well-received by our pharmaceutical partners and end users.”
About BioQ Pharma
BioQ Pharma Incorporated is a privately held specialty pharmaceutical company focused on developing and commercializing ready-to-use infusible pharmaceuticals. The Company's infusion platform is intended to address some of the most pressing unmet needs in drug infusion today: cost, medication error, sterility, efficiency, and patient quality of life. BioQ Pharma's vision is to set a new standard of care in the presentation and administration of infusible pharmaceuticals via the Company's proprietary unit-dose infusion systems that can be deployed quickly and conveniently at the point of care with one touch. The Company is ISO13485 certified. BioQ Pharma's commercial collaborators and strategic partners include Novartis' Sandoz unit, Stada, Cipla, Lee's Pharm, Lunatus, Galen Limited, and West Pharmaceutical Services.
BioQ Pharma Contact Information:
President and CEO
Chief Financial Officer
Chief Commercial Officer
Phone: +32 474 (053) 253